7th edition of the Anti-Thrombosis
Bucharest, Romania on the 3rd July 2015.
Scientific Coordination: Dr. Juan Vicente Llau, Spain.
ROVI organizes the 7th edition of the educational forum Anti-Thrombosis Masterclass, addressed to international experts in the thromboembolism field, into a university environment and including cutting edge presentations related to venous thromboembolism by well respected international opinion leaders. This year’s meeting will be chaired by Dr. Juan V. Llau (Anesthesiologist & Critical Care Department, Clinic University Hospital of Valencia, Spain), who has participated in this activity since 2009.
This seminar will have 7 theoretical lectures in the morning integrated in 3 different modules and a practical 4th Module in the afternoon, with interactive workshops based in case reports in daily clinical practice.
REGISTER HERE AND JOIN THE COURSE FOR FREE.
Your information is confidential, we are committed to protecting your privacy.
Dr. Juan Vicente Llau
Professor Llau is an anaesthesiologist and Section Chief of the Department of Anaesthesia and Post-Surgical Critical Care at the Hospital Clinico Universitario, Valencia, Spain, and is Associated Professor of Human Physiology at the University of Valencia.
Professor Llau received his medical degree in Valencia, Spain, in 1986, where he studied anaesthesiology at the Hospital La Fe, becoming an anaesthesiologist in 1993. His research interests are thrombosis and hemostasis and transfusion practice.
He is a member of several groups involved in the study of transfusion practice and hemostasis management including the Haemostasis Subcommittee of the European Society of Anaesthesiology (ESA). He is also a member of the board of examiners for the ESA European Diploma of Anaesthesiology. Professor Llau has been the founder and the Vice President of the Transfusion and Haemostasis section of the Spanish Society of Anaesthesiology, and is a reviewer and secretary for REDAR (Revista Española de Anestesiología y Reanimación), the official journal of the Spanish Society of Anaesthesiology. He has published over 150 papers and book chapters relating to transfusion practice and thrombosis and hemostasis. He is the editor of five books on transfusion and haemostasis medicine, the last one entitled “Thromboembolism in Orthopedic Surgery”, published in 2013.
Dr. Juan Vicente Llau, Spain (Chairman)
Anesthesiology and Critical Care Department. Clinic University Hospital of Valencia, Spain.
Dr. Jerrold Levy
Jerrold H. Levy received his undergraduate degree from the University of Michigan, and his medical degree from the University of Miami where he served a postdoctoral internship in internal medicine at Jackson Memorial Hospital. He completed a residency in Anesthesiology at Massachusetts General Hospital/Harvard, Boston, where he was also Chief Resident and completed two fellowships in Respiratory Intensive Care with Professors Henning Pontopiddan and Warren Zapol, and in Cardiac Anesthesiology with Professor Edward Lowenstein.
Dr. Levy joined the faculty of Duke University in 2013, and is Professor of Anesthesiology, Associate Professor of Surgery, and CoDirector of the Cardiothoracic ICU. He was on the Emory faculty from 1983-2013, and was Deputy Chairman for Research in the Department of Anesthesiology at Emory University School of Medicine from 1995-2013, and served as the Director of Cardiothoracic Anesthesiology Division and an Attending Physician in the Cardiothoracic Intensive Care Unit.
He is a Fellow of the American Heart Association, a Fellow of American College of Critical Care Medicine, and a member of the Leadership Committee of the American Heart Association Council on Cardiovascular Surgery & Anesthesia. He is an elected member of the Shock Society, and serves as a consultant to the FDA (CBER). Dr. Levy is currently is on the Executive Editorial Board for Anesthesiology and on the Editorial Boards of Anesthesia Analgesia where he previously served as Section Editor for Hemostasis and Transfusion Medicine. He is also a consultant reviewer for many other journals in the areas of hemostasis, inflammation, anaphylaxis, and cardiovascular pharmacology. He is the recipient of multiple awards, including the Harvard Prize Book Award, American Cancer Society Research Fellowship, M. Jasinska Award from Massachusetts General Hospital, and the 3M New Investigator Award. He is also on the Board of the Foundation of the Society of Cardiovascular Anesthesiology.
Dr. Levy’s research interests include anticoagulation, hemostasis, acute inflammation/ anaphylactic reactions, cardiovascular pharmacology, and vascular physiology. He has been active in developing novel approaches to anticoagulation and reversal. Some of his current research efforts are the application of purified and recombinant biotechnology in clinical medicine to prevent or treat bleeding, understanding mechanisms of thrombin signaling and its modulation, and developing novel strategies for anticoagulation and its reversal. Dr. Levy has written two textbooks on Anaphylaxis, edited three others on Critical Care, recently editing one on Anticoagulation for Clinics in Laboratory Medicine. He has published over 400 journal articles, reviews, monographs, textbook chapters, editorials, abstracts, and other publications. As an invited speaker, he has lectured extensively all over the world. He is fluent in English and French, and speaks conversational Spanish and Japanese.
Dr. Jerrold Levy, USA
Professor of Anesthesiology, Associate Professor of Surgery, and CoDirector of the Cardiothoracic ICU. Duke University, USA.
Dr. Jawed Fareed
Dr. Jawed Fareed is a Professor of Pathology & Pharmacology and Director of the Hemostasis & Thrombosis Research Laboratories at Loyola University Health Science Division at the Stritch School of medicine in Maywood, Illinois, USA.
Dr. Fareed received his initial graduate training at the University of London, England and at the University of Guelph in Ontario, Canada. His doctorate degree was completed at Loyola University Chicago in the areas of Pharmacology and Experimental Therapeutics in 1974 and is currently pursuing research, teaching and service activities. In June 1996, Dr. Fareed received the degree of Doctor Honoris Causa from the University of Bordeaux in France. He has received numerous awards from various national and international organizations.
Dr. Fareed’s main area of interest is research in the development of novel anticoagulant and antithrombotic drugs. He has devoted much of his activities to the initial studies on the characterization of heparin and related drugs, low molecular weight heparin and synthetic heparin derivatives such as the pentasaccharide. He has also contributed to the development of several newer antithrombotic drugs.
He is an author or co-author of some 600 publications in the area of antithrombotic drug pharmacology. He has authored several textbooks and has published extensively in the area of hemostasis and thrombosis. Dr. Fareed’s professional affiliations included membership of the expert panel on biologicals for the World Health Organization in Geneva, Switzerland and institutional delegate to the USP. He acts as an advisor to several regulatory agencies globally. He is a recipient of several national and international awards, including the Sam Natelson Award of the American Association of Clinical Chemistry and the IUA 2002 Lectureship. He is an elected fellow of the International Union of Angiology and the American College of Angiology. He is a fellow of the American Heart Association. He is a recipient of the distinguished services award from the South Asian Society of Thrombosis.
Dr. Jawed Fareed, USA
Professor of Pathology & Pharmacology and Director of the Hemostasis & Thrombosis Research Laboratories at Loyola University Medical Center. USA
Dr. Davide Imberti
Davide Imberti is the director of the Internal Medicine Unit and of the Haemostasis and Thrombosis Center of the Hospital of Piacenza, Italy.
Dr Imberti is member of a number of national and international professional societies (including the International Society on Thrombosis and Haemostasis), member of the National Executive Committee of the Italian Society of Atherosclerosis Thrombosis Vascular Biology (ATBV) and past-member of the National Executive Committee of the Italian Society for the Study of Haemostasis and Thrombosis (SISET).
Dr Imberti acts as a reviewer for several medical journals, including Journal of Thrombosis and Haemostasis, Archives of Internal Medicine, Haematologica, Journal on Emergency Medicine, Thrombosis and Haemostasis, Chest, Transfusion, Thrombosis Research; Clin Appl Thromb Haemost. He is chair of the guidelines committee of the Italian Society for the Study of Haemostasis and Thrombosis (SISET) about treatment of thrombosis in cancer patients.
He is Author/Co-author of more than 150 papers published in peer reviewed medical and scientific journals. His current research activities include especially the clinical evaluation of new antithrombotic drugs and the management of warfarin and new oral anticoagulants related haemorrhagic complications. He participates as principal investigator or cohordinator to several international and national multicenter studies regarding venous and arterial thromboembolism and bleeding disorders.
He is member of the regional committee for the antithrombotic drugs, of the regional group for management of venous thromboembolism in surgical and orthopaedic patients and of the regional group for management of thrombophilia.
Dr. Davide Imberti , Italy
Hemostasis and Thrombosis Center. Internal Medicine Department, Piacenza Hospital, Italy.
Dr. Andrés Muñoz
Andrés J. Muñoz Martín is currently consultant of the Gastrointestinal Cancer Unit at the Hospital General Universitario Gregorio Marañón (Madrid, Spain).
He earned his medical degree from the Universidad Autónoma de Madrid (Spain) and biostatistics for the health sciences degree from the Universidad Autónoma de Barcelona (Spain). He trained in oncology at the Hospital General Universitatio Gregorio Marañón of Madrid.
Head of research program of cancer&thrombosis and cancers of the Pancreas and Hepatobiliary Tract.
Coordinator of the Cancer&Thrombosis Working Group of the Spanish Society of Medical Oncology.
Dr. Muñoz’s professional interest include modeling the individual risk of venous thromboembolism in cancer patients receiving chemotherapy in ambulatory setting and gastrointestinal cancers.
Dr. Andrés Muñoz, Spain
Gastrointestinal Cancer Unit, Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Spain.
Dr. Ersin Özaslan
Dr. Ersin Özaslan is medical oncologist from Erciyes University Hospital (Turkey).
Dr. Özaslan received his medical degree in Istanbul University School of Medicine in 2007, Turkey. In 2012, he also obtained the internal medicine specialty, M.D in Erciyes University Hospital, where he continues his research as a medical oncologist.
He is Author/Co-author of many International Publications for medical and scientific journals. Between his publications we can mentioned the following:
Factors affecting prognosis in metastatic colorectal cancer patients.
Analyses of multiple factors for determination of “selected patients” who should receive rechallenge treatment in metastatic colorectal cancer: a retrospective study from Turkey. Ozaslan E, Duran AO, Bozkurt O, Inanc M, Ucar M, Berk V, Karaca H, Elmali F, Ozkan M. Asian Pac J Cancer Prev. 2015;16(7):2833-8.
Salvage chemotherapy with weekly Paclitaxel for metastatic melanoma.
Psychological distress and loneliness in caregiver of advanced oncological inpatients.
Clinicopathological characteristics and prognosis of patients according to recurrence time after curative resection for colorectal cancer.
He is currently one of the main investigators in the TREBECA Study (Effectiveness And Safety of LMWH Treatment in Cancer Patients Diagnosed With Non-High Risk Venous Thromboembolism)
Dr. Ersin Özaslan, Turkey
Medical Oncology Service, Erciyes University Hospital, Turkey.
Dr. Elena Copaciu
Dra. Elena Copaciu, is Head of Anesthesia and Intensive Care Department at the University Emergency Hospital, Carol Davila University of Medicine Bucharest, Romania
She is President of the Romanian Association for the Study of Pain- RASP (IASP/EFIC chapter) and also President of Anesthesia and Intensive Care Committee of the Romanian College of Physicians (since 2006).
Dra. Copaciu is a National representative in the European Board of Anesthesiologists( EBA), on behalf of the Romanian Society of Anesthesia and Intensive Care ( RSAIC). Also EBA representative in the UEMS Multidisciplinary Joint Committee on Pain Management.
She has participated in many projects. For example: She was Project director- “Pro Paincontrol”- final objective- to initiate the activities of four Acute Pain Centers in four university hospitals in Romania. She also was Coordinator of the RASP/RSAIC joint working groups on Good Clinical Practice Statements on Postoperative and Labour Analgesia, Postoperative analgesia in the addicted patients, Safe Perioperative use of NSAIDs
Dra. Elena Copaciu is Member of the working group on the new opioid law in Romania( 2002-2005). And also National Coordinator of the National Healthcare Insurance House Programme on invasive neuromodulation in refractory pain syndromes- 2013.
Dr. Elena Copaciu, Romania
Head of Anesthesia and Intensive Care Department at the University Emergency Hospital and Assoc Prof at Carol Davila University of Medicine Bucharest, Romania.
2nd July 2015
19.30 – 20.30 Welcome Reception (Rovi)
20.30 – 22.30 Dinner
3rd July 2015
09.00-09.15 Welcome & introduction
09.15-10.15 MODULE 1. PATHOPHYSIOLOGY OF VTE AND HISTORIC PERSPECTIVE OF LMWHs
10.15-11.15 MODULE 2. SURGICAL THROMBOPROPHYLAXIS
11.15-11.45 Coffee Break
11.45-13.15 MODULE 3. CANCER AND THROMBOSIS
– Management of cancer-associated thrombosis (Dr. D. Imberti, Italy)
– Cancer & thrombosis: Role of LMWHs in the prevention and treatment of VTE (Dr. A. Muñoz, Spain)
– Outpatient care for VTE treatment in cancer patients (Dr. E. Özaslan, Turkey.)
– Long-term management of VTE in the elderly (Dr. D. Imberti, Spain)
13.15-13.30 Closing remarks
15.00-18.00 MODULE 4. SPECIAL POPULATIONS. WORKSHOPS
Dr. J.V. Llau: Cancer surgery: Duration of thromboprophylaxis.
Dr. J. Levy: Thrombotic and bleeding risk stratification in the perioperative period
Dr. E. Özaslan: Long-term and outpatient treatment of VTE
Dr. D. Imberti: Special populations management in VTE
Dr. A. Muñoz: Cancer & thrombosis: long-term treatment of VTE
Dr. E. Copaciu: Orthopaedic surgery: Optimal initiation of thromboprophylaxis